LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

62.27 0.37

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

61.48

Massimo

62.39

Metriche Chiave

By Trading Economics

Entrata

-6.2M

-49M

Vendite

-9.1M

33M

EPS

-0.81

Margine di Profitto

-151.352

Dipendenti

283

EBITDA

-9.5M

-47M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+32.37% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-174M

3.9B

Apertura precedente

61.9

Chiusura precedente

62.27

Notizie sul Sentiment di mercato

By Acuity

71%

29%

350 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mag 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23 mag 2025, 21:57 UTC

Azioni calde

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 mag 2025, 21:15 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mag 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 mag 2025, 20:56 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Salesforce Back in Deal Talks With Informatica -- WSJ

23 mag 2025, 20:51 UTC

Notizie principali

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 mag 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

23 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 mag 2025, 20:41 UTC

Notizie principali

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 mag 2025, 20:28 UTC

Notizie principali

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 mag 2025, 20:06 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 mag 2025, 20:06 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 mag 2025, 19:50 UTC

Notizie principali

Trump's Tariffs: Where Things Stand -- 16th Update

23 mag 2025, 19:28 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 mag 2025, 19:28 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 mag 2025, 19:27 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 mag 2025, 19:20 UTC

Discorsi di Mercato

Crude Futures Post Modest Weekly Losses -- Market Talk

23 mag 2025, 19:18 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 mag 2025, 18:57 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mag 2025, 18:54 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 mag 2025, 18:53 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 mag 2025, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 mag 2025, 18:13 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

23 mag 2025, 18:13 UTC

Discorsi di Mercato

Gold Trades Higher on Reminder of Risk -- Market Talk

23 mag 2025, 18:00 UTC

Notizie principali

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 mag 2025, 17:51 UTC

Discorsi di Mercato
Utili

Workday Sees Higher Bar for Guidance -- Market Talk

23 mag 2025, 17:42 UTC

Notizie principali

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23 mag 2025, 17:39 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23 mag 2025, 17:07 UTC

Notizie principali

Trump's Tariffs: Where Things Stand -- 15th Update

23 mag 2025, 17:04 UTC

Discorsi di Mercato
Utili

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

32.37% in crescita

Previsioni per 12 mesi

Media 82.08 USD  32.37%

Alto 94 USD

Basso 72 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

12

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

350 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.